Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 716 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sequential Therapy Clear all
Active, not recruiting Phase 3 Interventional

Fluoxetine vs CBT in Childhood Anxiety Disorders

NCT04760275
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Fluoxetine, Cognitive Behavioral Therapy (CBT)
Drug · Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 17 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neurosteroid Intervention for Menopausal and Perimenopausal Depression

NCT03505905
View directory record Official record
Conditions
Major Depressive Disorder, Menopause, Perimenopause
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 67 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional

Study of DF9001 in Patients With Advanced Solid Tumors

NCT05597839
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
DF9001, KEYTRUDA® (pembrolizumab)
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Gilbert, Arizona • Phoenix, Arizona • Irvine, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2 Interventional

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)

NCT00370383
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
70 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
11
States / cities
Anaheim, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 30, 2026, 2:32 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

NCT06442566
View directory record Official record
Conditions
Opioid Withdrawal, Chronic Pain
Interventions
Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS)
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

NCT00884234
View directory record Official record
Conditions
Lateral Canthal Lines
Interventions
Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
Other · Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders

NCT00587054
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

NCT02224053
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Omeprazole tablet dosing, Pharmacokinetic sampling - AZ5140 and AZ7550
Procedure · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

NCT01776723
View directory record Official record
Conditions
Myelomonocytic Leukemia
Interventions
Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
6
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Oct 30, 2026, 2:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection

NCT01723059
View directory record Official record
Conditions
Helicobacter Infection
Interventions
Standard Triple Therapy, Sequential Therapy
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 4 Interventional

Sequenced Treatment Alternatives to Relieve Depression (STAR*D)

NCT00021528
View directory record Official record
Conditions
Depression
Interventions
citalopram, BuproprionSR, buspirone, Lithium, mirtazapine, nortriptyline, sertraline, tranylcypromine, VenlafaxineXR, Cognitive Therapy, T3 (Triiodothyronine)
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Chula Vista, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2009 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

NCT00635050
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Doxil, Paclitaxel, Cyclophosphamide, Avastin
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 30, 2026, 2:32 PM EDT
Completed No phase listed Observational

Radiomics: a Study of Outcome in Lung Cancer

NCT01302626
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Maastricht Radiation Oncology
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 30, 2026, 2:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
TSN1611
Drug
Lead sponsor
Tyligand Pharmaceuticals (Suzhou) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

CNS10-NPC-GDNF for the Treatment of ALS

NCT02943850
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Stem cell (HPC) implantation, Stereotactic surgical device
Biological · Device
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

NCT01495169
View directory record Official record
Conditions
Safety and Tolerability of Iloperidone
Interventions
iloperidone (oral tablet)
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • North Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

NCT02144051
View directory record Official record
Conditions
Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Interventions
AZD5312
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Sarasota, Florida • Nashville, Tennessee • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 30, 2026, 2:32 PM EDT
Recruiting No phase listed Observational

A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)

NCT06351605
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
Valeda® Light Delivery System
Device
Lead sponsor
LumiThera, Inc.
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Beverly Hills, California • Cincinnati, Ohio • Charleston, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 2:32 PM EDT
Terminated Phase 1Phase 2 Interventional

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

NCT00899977
View directory record Official record
Conditions
Refractory Hypertension
Interventions
Placebo, TC-5214
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

NCT02185053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CPC-201
Drug
Lead sponsor
Chase Pharmaceuticals Corporation, an affiliate of Allergan plc
Industry
Eligibility
50 Years to 79 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 30, 2026, 2:32 PM EDT
Not listed Phase 1 Interventional

Treatment of Conduct Problems and Depression

NCT01267773
View directory record Official record
Conditions
Depression, Oppositional Defiant Disorder, Conduct Disorder
Interventions
Integrated Treatment
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
8 Years to 14 Years
Enrollment
30 participants
Timeline
2010 – 2013
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

NCT03928353
View directory record Official record
Conditions
Healthy
Interventions
PB2452 Infusion, Placebo - Sodium Chloride, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 30, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

NCT00004186
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, etoposide, ifosfamide, topotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 30, 2026, 2:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

NCT01708161
View directory record Official record
Conditions
PIK3CA Mutated Advanced Solid Tumors, PIK3CA Amplified Advanced Solid Tumors
Interventions
BYL719, AMG 479
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 30, 2026, 2:32 PM EDT